retatrutide clinical trials status 2025 Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Retatrutide vs Ozempic: Clinical Trial
Description
2023 Sep 10;21(3):15593258231200527
Light, protein-rich breakfast ideas for people using GLP-1 medications that support weight loss, reduce nausea, and keep energy steady all morning.
Retatrutide produces the greatest weight loss (up to 24.2%), followed by tirzepatide (up to 22.5%), then semaglutide (up to 14.9%), but retatrutide remains i...
Open access peer-reviewed chapter
Refrigerated (2C 8C)
